Pörssitiedote26.1.2024 klo 11.09All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
Lehdistötiedote20.12.2023 klo 14.02Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
Lehdistötiedote12.12.2023 klo 16.11Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
Pörssitiedote20.11.2023 klo 7.03Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
Pörssitiedote10.10.2023 klo 6.08Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
Pörssitiedote27.9.2023 klo 7.23Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP
Pörssitiedote4.9.2023 klo 9.48Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
Pörssitiedote30.3.2023 klo 16.07Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner
Pörssitiedote30.3.2023 klo 15.57Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S
Pörssitiedote30.3.2023 klo 11.11Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders
Pörssitiedote28.3.2023 klo 10.07Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion
Pörssitiedote8.3.2023 klo 7.00Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company